je.st
news
Tag: merck
Merck to Participate at the Morgan Stanley Global Healthcare Conference
2014-09-08 23:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer; Adam H. Schechter, executive vice president and president, Global Human Health; and Dr. Roy Baynes, senior vice president, Clinical Development, Merck Research Laboratories, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York on Sept. 9, 2014 at 8:00 a.m. EDT. Language: English Contact: MerckMedia:Lainie Keller, 308-423-4187orInvestors:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: global
conference
participate
morgan
FDA OKs Merck drug for melanoma, 1st in new cancer drug class
2014-09-04 23:14:34| Biotech - Topix.net
Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
Merck Receives Accelerated Approval of KEYTRUDA (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
2014-09-04 21:15:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: approval
therapy
receives
accelerated
4-H Members Receive Merck Awards For Ag Advocacy
2014-09-03 20:00:44| Beef
Four top 4-H members were proud winners of the inaugural Young Advocates for Agriculture Award, sponsored by Merck Animal Health. The Merck award recognizes grassroots efforts by 4-H members to support agriculture. Sarah Schuster of Dane County, WI, was the inaugural award winner. She was honored for educating youth leaders and other 4-H members about the significance and value of science and technology in agriculture. Other finalists were Jacob Newkirk of Cumberland County, NJ, and Margaret Brownell and Kaylah Gulley, of Washington County, NY. read more
Tags: members
receive
awards
advocacy
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab
2014-09-03 05:50:17| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company's investigational anti-PD-1 antibody, at the European Society of Medical Oncology 2014 in Madrid, Spain, September 26 - 30. Data on pembrolizumab are ... (more)
Tags: data
present
types
studies
Sites : [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] next »